Karyopharm Therapeutics
Natasha Royal holds a Master's in Public Health and a Master of Business Administration, along with a certificate in Regulatory Affairs. Currently serving as Senior Manager in Regulatory Advertising/Promotion & Labeling at Karyopharm Therapeutics Inc. since September 2020, Natasha also works as Global Labeling Lead with Sciformix under contract with Pfizer. Prior experience includes roles as Global Regulatory Labelling Specialist at Indivior, Regulatory Associate for Global Labeling at Reckitt Benckiser, and Clinical Research Coordinator & Unblinded Pharmacist at the Institute for Asthma and Allergy PC. Natasha's educational background includes a Bachelor of Science in Biology and Chemistry from Virginia Union University.
This person is not in any offices
Karyopharm Therapeutics
13 followers
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).